David Greer is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
185 Chateau Dr SW Ste 301
Huntsville, AL 358017413
Telephone
256-265-2695Provider last certified this registry record 17 Jan 2020.
Clinical trials
- Neuroprognostication Bias: A Collaboration to Reduce the Impact of Self-fulfilling Prophecy in Cardiac ARrEst
Sponsor: Boston Medical Center
- Impact of Fever Prevention in Brain Injured Patients
Sponsor: C. R. Bard
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
92 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202555 payments
- PFIZER INC.Program year202532 payments
- Medtronic, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
81.1%Neuromuscular Blocker80.5%Onabotulinumtoxina55%Abobotulinumtoxina45%Part B, office-administered≥34 patientsgamma-Aminobutyric Acid-ergic Agonist0.3%Baclofen100%Part D≥23 patients+ 3 more classes in this area
Nervous system
17.4%Other antiepileptics2.8%Levetiracetam41%Lacosamide31%Topiramate10%Briviact9%Xcopri4%Levetiracetam Er3%Epidiolex1%Part D<11 patientsAromatic Amino Acid Decarboxylation Inhibitor1.7%Carbidopa-Levodopa70%Carbidopa-Levodopa Er17%Rytary10%Carbidopa3%Part D<11 patients+ 35 more classes in this area
Cardiovascular
0.3%Beta blocker0.2%Propranolol Hcl73%Propranolol Hcl Er27%Part D<11 patientsStatin0.1%Atorvastatin Calcium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”